Elucida Oncology to Present at Two Upcoming Conferences
03. Juni 2022 10:00 ET
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that...
Elucida Oncology to Present Trials in Progress Poster for Phase 1/2 Study of ELU001 in Patients with Advanced, Recurrent, or Refractory Cancers Overexpressing FRα at 2022 American Society of Clinical Oncology Annual Meeting
01. Juni 2022 13:30 ET
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today the...
Elucida Oncology to Present at the Bank of America 2022 Healthcare Conference
06. Mai 2022 11:00 ET
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N. J. , May 06, 2022 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that...
Elucida Oncology’s Lead Clinical Candidate ELU001 to Be Featured in Two Abstracts at the American Association for Cancer Research Annual Meeting
04. April 2022 10:00 ET
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., April 04, 2022 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today two...
Elucida Oncology to Present at Two Upcoming Scientific Conferences
03. März 2022 13:30 ET
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that Dr....
Elucida Oncology Provides Corporate Update and Outlines Key Upcoming Milestones
05. Januar 2022 08:02 ET
|
Elucida Oncology, Inc
Enrolling third dose level in Phase 1/2 dose escalation study of ELU001, our lead clinical program targeting solid tumors overexpressing folate receptor alpha (FRα) Interim Phase 1 data for ELU001 in...
Elucida Oncology to Present at Two Upcoming Investor Conferences
05. Januar 2022 08:00 ET
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that Geno...
Elucida Oncology to Present Preclinical Data on ELU001 at the Antibody Engineering & Therapeutic Conference
15. Dezember 2021 15:50 ET
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that...
Elucida Oncology Appoints Ian Somaiya as Chief Financial Officer and Chief Business Officer
22. November 2021 07:30 ET
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today the...
Elucida Oncology Announces First Patient Dosed in Phase 1/2 Study of ELU001 in Patients with Advanced, Recurrent, or Refractory Cancers Overexpressing Folate-Receptor Alpha (FRα)
17. September 2021 10:15 ET
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Elucida Oncology, a biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that it has completed...